Drug name - Cometriq
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7579473 | EXELIXIS | c-Met modulators and methods of use |
Aug, 2026
(3 years from now) | |
| US11091439 | EXELIXIS | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
Jan, 2030
(7 years from now) | |
| US8877776 | EXELIXIS | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
Oct, 2030
(8 years from now) | |
| CN102388024A | EXELIXIS | Malate Salt Of N-(4-{[6,7-Bis (Methyloxy) Quinolin-4-Yl] Oxy} Phenyl-N'-(4-Fluorophenyl) Cyclopropane-1-Dicarboxamide, And Crystalline Forms Thereof For The Treatment Or Cancer |
Sep, 2019
(3 years ago) | |
| CN106083714B | EXELIXIS | N --(4 - [6, 7 --(Methyl Oxy) Quinoline - -4--- Yl] Oxy} Phenyl) -N '--(4 - - Fluorophenyl) -1, 1-Dimethanamide Malate And Its Crystalline |
May, 2022
(4 months ago) | |
| CN106083714A | EXELIXIS | N - (4 - {[6, 7-Bis - (Methyl) -4 - Yl] Oxy} Phenyl) -N '-(4) -1, 1 -- Dicarboxamide Malate And Its Crystal |
May, 2022
(4 months ago) | |
| EP2392565A1 | EXELIXIS | C-Met Modulators And Methods Of Use |
Sep, 2024
(1 year, 11 months from now) | |
| EP2210607A1 | EXELIXIS | N-[3-Fluoro-4-({6-(Methyloxy)-7-[(3-Morpholin-4-Ylpropyl)Oxy]Quinolin-4-Yl}Oxy)Phenyl]-N'-(4-Fluorophenyl)Cyclopropane-1,1-Dicarboxamide For The Treatment Of Cancer |
Sep, 2024
(1 year, 11 months from now) | |
| EP2210607B1 | EXELIXIS | N-[3-Fluoro-4-({6-(Methyloxy)-7-[(3-Morpholin-4-Ylpropyl)Oxy]Quinolin-4-Yl}Oxy)Phenyl]-N'-(4-Fluorophenyl)Cyclopropane-1,1-Dicarboxamide For The Treatment Of Cancer |
Sep, 2024
(1 year, 11 months from now) | |
| EP1673085A4 | EXELIXIS | C-Met Modulators And Methods Of Use |
Sep, 2024
(1 year, 11 months from now) | |
| EP3329918A3 | EXELIXIS | C-Met Modulators And Methods Of Use |
Sep, 2024
(1 year, 11 months from now) | |
| EP2409704B1 | EXELIXIS | C-Met Modulators And Methods Of Use |
Sep, 2024
(1 year, 11 months from now) | |
| EP2392565B1 | EXELIXIS | C-Met Modulators And Methods Of Use |
Sep, 2024
(1 year, 11 months from now) | |
| EP2392564A1 | EXELIXIS | C-Met Modulators And Methods Of Use |
Sep, 2024
(1 year, 11 months from now) | |
| EP3329918A2 | EXELIXIS | C-Met Modulators And Methods Of Use |
Sep, 2024
(1 year, 11 months from now) | |
| EP1673085B1 | EXELIXIS | C-Met Modulators And Methods Of Use |
Sep, 2024
(1 year, 11 months from now) | |
| EP2409704A3 | EXELIXIS | C-Met Modulators And Methods Of Use |
Sep, 2024
(1 year, 11 months from now) | |
| EP2392564B1 | EXELIXIS | C-Met Modulators And Methods Of Use |
Sep, 2024
(1 year, 11 months from now) | |
| EP1673085A2 | EXELIXIS | C-Met Modulators And Methods Of Use |
Sep, 2024
(1 year, 11 months from now) | |
| EP2409704A2 | EXELIXIS | C-Met Modulators And Methods Of Use |
Sep, 2024
(1 year, 11 months from now) | |
| EP3329918B1 | EXELIXIS | C-Met Modulators And Methods Of Use |
Sep, 2024
(1 year, 11 months from now) | |
| EP2213661B1 | EXELIXIS | C-Met Modulators And Methods Of Use |
Mar, 2029
(6 years from now) | |
| EP2213661A1 | EXELIXIS | C-Met Modulators And Methods Of Use |
Mar, 2029
(6 years from now) | |
| EP2387563A1 | EXELIXIS | Malate Salt Of N- (4- { [ 6, 7-Bis (Methyloxy) Quinolin-4-Yl]Oxy}Phenyl-N' - (4 -Fluorophenyl) Cyclopropane-1,1-Dicarboxamide, And Crystalline Forms Thereof For The Treatment Of Cancer |
Jan, 2030
(7 years from now) | |
| EP2387563B2 | EXELIXIS | Malate Salt Of N- (4- { [ 6, 7-Bis (Methyloxy) Quinolin-4-Yl]Oxy}Phenyl-N' - (4 -Fluorophenyl) Cyclopropane-1,1-Dicarboxamide, And Crystalline Forms Thereof For The Treatment Of Cancer |
Jan, 2030
(7 years from now) | |
| EP2387563B1 | EXELIXIS | Malate Salt Of N- (4- { [ 6, 7-Bis (Methyloxy) Quinolin-4-Yl]Oxy}Phenyl-N' - (4 -Fluorophenyl) Cyclopropane-1,1-Dicarboxamide, And Crystalline Forms Thereof For The Treatment Of Cancer |
Jan, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11098015 | EXELIXIS | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
Jan, 2030
(7 years from now) | |
| US11091440 | EXELIXIS | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer |
Jan, 2030
(7 years from now) | |
| US9717720 | EXELIXIS | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
Feb, 2032
(9 years from now) | |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
Treatment: Method of treating medullary thyroid cancer
Dosage: CAPSULE;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 20MG BASE | CAPSULE;ORAL | Prescription |
| EQ 80MG BASE | CAPSULE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.